Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P, Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, Sconocchia G, Lo-Coco F, Amadori S, Venditti A.
Maurillo L, et al. Among authors: del principe mi.
Am J Hematol. 2015 Feb;90(2):125-31. doi: 10.1002/ajh.23893. Epub 2014 Nov 24.
Am J Hematol. 2015.
PMID: 25377359
Free article.
Clinical Trial.